Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT02763566
- Locations
- 🇧🇷
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil
🇨🇳Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China
🇨🇳Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
Cardiovascular Outcomes of Low Testosterone
- Conditions
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 232
- Registration Number
- NCT02758431
- Locations
- 🇺🇸
University of Colorado CCTSI CTRC, Denver, Colorado, United States
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
- Conditions
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 72
- Registration Number
- NCT02730923
- Locations
- 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷ICO - Paul Papin, Angers, France
🇫🇷GHM Institut Daniel Hollard, Grenoble, France
A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 98
- Registration Number
- NCT02730091
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Midwestern Regional Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02689921
- Locations
- 🇺🇸
Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion, Illinois, United States
🇺🇸Southeastern Regional Medical Center, Newnan, Georgia, United States
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02648477
- Locations
- 🇺🇸
City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 120
- Registration Number
- NCT02585388
- Locations
- 🇫🇷
CHU de Grenoble, Grenoble, France
🇫🇷CHD Vendée, La Roche sur Yon, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Fondazione Sandro Pitigliani
- Target Recruit Count
- 115
- Registration Number
- NCT02549430
- Locations
- 🇮🇹
Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy
🇮🇹Istituto Europeo Oncologia, Milano, Italy
🇮🇹Ospedale Antonio Perrino, Brindisi, Italy
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT02476786
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 224
- Registration Number
- NCT02441946
- Locations
- 🇺🇸
Millennium Oncology, Houston, Texas, United States
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Taipei, Taiwan
🇺🇸Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.